Baidu
map

糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

奥马环素治疗糖尿病ABSSSI患者安全有效

2019-10-06 Allan MedSci原创

ABSSSI奥马环素糖尿病
关注

根据2019年美国传染病学会年会上发表的一项研究表明，无论糖尿病状态如何，奥马环素（Omadacycline）对患有急性细菌性皮肤结构感染（ABSSSI）的患者都是安全有效的。

根据2019年美国传染病学会年会上发表的一项研究表明，无论糖尿病状态如何，奥马环素（Omadacycline）对患有急性细菌性皮肤结构感染（ABSSSI）的患者都是安全有效的。密歇根大学医学博士Manjunath Pai及其同事分析了3项研究的数据：OASIS-1，该研究比较了口服和静脉内注射奥马环素和利奈唑胺制剂对成人ABSSSI的情况；OASIS-2，比较了口服奥马环素和口服利奈唑胺治疗ABSSSI的情况；OPTIC，该研究比较了口服和静脉内注射奥马环素和口服莫西沙星在社区获得性细菌性肺炎（CABP）中的治疗作用。

这项汇总分析共纳入2150名患者，其中有238名（11.1％）患有糖尿病。结果表明，无论患者是否患有糖尿病，奥马环素与比较药物（利奈唑胺或莫西沙星）在安全性和有效性方面是相似的。


原始出处：

http://www.firstwordpharma.com/node/1671987#axzz61Rlned4y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024025, encodeId=03012024025a6, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu May 21 21:45:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045159, encodeId=d0302045159b6, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 11 22:45:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649435, encodeId=33b016494350c, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Dec 27 07:45:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517156, encodeId=5868151e15648, content=<a href='/topic/show?id=2eca44583b2' target=_blank style='color:#2F92EE;'>#奥马环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44583, encryptionId=2eca44583b2, topicName=奥马环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35c211056018, createdName=ms6127405442416114, createdTime=Tue Oct 08 00:45:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042749, encodeId=348d1042e49c4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 06 12:45:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-05-21 huanbaofeng

    #ABSSSI#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2024025, encodeId=03012024025a6, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu May 21 21:45:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045159, encodeId=d0302045159b6, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 11 22:45:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649435, encodeId=33b016494350c, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Dec 27 07:45:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517156, encodeId=5868151e15648, content=<a href='/topic/show?id=2eca44583b2' target=_blank style='color:#2F92EE;'>#奥马环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44583, encryptionId=2eca44583b2, topicName=奥马环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35c211056018, createdName=ms6127405442416114, createdTime=Tue Oct 08 00:45:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042749, encodeId=348d1042e49c4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 06 12:45:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-05-11 医者仁心

    #患者安全#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2024025, encodeId=03012024025a6, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu May 21 21:45:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045159, encodeId=d0302045159b6, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 11 22:45:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649435, encodeId=33b016494350c, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Dec 27 07:45:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517156, encodeId=5868151e15648, content=<a href='/topic/show?id=2eca44583b2' target=_blank style='color:#2F92EE;'>#奥马环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44583, encryptionId=2eca44583b2, topicName=奥马环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35c211056018, createdName=ms6127405442416114, createdTime=Tue Oct 08 00:45:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042749, encodeId=348d1042e49c4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 06 12:45:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-12-27 nymo

    #SSI#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2024025, encodeId=03012024025a6, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu May 21 21:45:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045159, encodeId=d0302045159b6, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 11 22:45:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649435, encodeId=33b016494350c, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Dec 27 07:45:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517156, encodeId=5868151e15648, content=<a href='/topic/show?id=2eca44583b2' target=_blank style='color:#2F92EE;'>#奥马环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44583, encryptionId=2eca44583b2, topicName=奥马环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35c211056018, createdName=ms6127405442416114, createdTime=Tue Oct 08 00:45:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042749, encodeId=348d1042e49c4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 06 12:45:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-10-08 ms6127405442416114

    #奥马环素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2024025, encodeId=03012024025a6, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu May 21 21:45:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045159, encodeId=d0302045159b6, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 11 22:45:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649435, encodeId=33b016494350c, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Dec 27 07:45:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517156, encodeId=5868151e15648, content=<a href='/topic/show?id=2eca44583b2' target=_blank style='color:#2F92EE;'>#奥马环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44583, encryptionId=2eca44583b2, topicName=奥马环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35c211056018, createdName=ms6127405442416114, createdTime=Tue Oct 08 00:45:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042749, encodeId=348d1042e49c4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 06 12:45:00 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-10-06 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Iclaprim不会在ABSSSI患者中引起高钾血症

Iclaprim是一种新型的二氨基嘧啶，可选择性抑制细菌二氢叶酸还原酶，根据2019年美国传染病学会年会上发表的一项研究，Iclaprim治疗急性细菌性皮肤结构感染（ABSSSI）患者时不会引起高钾血症。

Baidu
map
Baidu
map
Baidu
map